Geron Corporation - Common Stock (NQ:GERN)

0.8944 -0.0556 (-5.85%)

Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Geron Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

October 12, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

Klotho Protein Emerges as a Potential Powerhouse In the Next Generation of Longevity Medicine

September 30, 2026

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:BIOA),(NASDAQ:GERN),(NASDAQ:DNLI) EQNX::TICKER_END

Via FinancialNewsMedia

Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

September 14, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

May 20, 2026

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:BIOA),(NYSE:LCTX),(NASDAQ:FATE) EQNX::TICKER_END

Via FinancialNewsMedia

Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone

March 03, 2026

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:NTLA),(NASDAQ:NAGE),(NASDAQ:OCGN) EQNX::TICKER_END

Via FinancialNewsMedia

Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 05, 2025

From Geron Corporation

Via Business Wire

Geron Corporation to Present at Upcoming Investor Conferences

November 04, 2025

From Geron Corporation

Via Business Wire

Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid Hematologic Malignancies

November 03, 2025

From Geron Corporation

Via Business Wire

Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025

October 27, 2025

From Geron Corporation

Via Business Wire

GERON (GERN) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

October 23, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 20, 2025

From Geron Corporation

Via Business Wire

Geron to Participate in the 2025 Wells Fargo Healthcare Conference

August 27, 2025

From Geron Corporation

Via Business Wire

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 18, 2025

From Geron Corporation

Via Business Wire

GERON (GERN) ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

August 13, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 08, 2025

From Geron Corporation

Via Business Wire

Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 06, 2025

From Geron Corporation

Via Business Wire

Geron Appoints Harout Semerjian as President and Chief Executive Officer

August 06, 2025

From Geron Corporation

Via Business Wire

Geron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025

July 28, 2025

From Geron Corporation

Via Business Wire

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 18, 2025

From Geron Corporation

Via Business Wire

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 18, 2025

From Geron Corporation

Via Business Wire

Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program

May 28, 2025

From Geron Corporation

Via Business Wire

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 19, 2025

From Geron Corporation

Via Business Wire

GERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

May 15, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

May 12, 2025

From Faruqi & Faruqi, LLP

Via Business Wire

Faruqi & Faruqi Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025 - GERN

May 11, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

GERN Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Geron Corporation (GERN) Investors of Filing Deadline in Class Action Lawsuit

May 10, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

GERN Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Geron Corporation (GERN) Investors of Filing Deadline in Class Action Lawsuit

May 10, 2025

Via TheNewswire.com

Topics Lawsuit

INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Geron Corporation and Certain Officers – GERN

May 09, 2025

From Pomerantz LLP

Via GlobeNewswire

GERN Investors Have Opportunity to Join Geron Corporation Fraud Investigation with the Schall Law Firm

May 08, 2025

From The Schall Law Firm

Via Business Wire

GERN Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds Geron Corporation (GERN) Investors of Filing Deadline in Class Action Lawsuit

May 08, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.